10x Genomics, Inc.

NasdaqGS:TXG Rapport sur les actions

Capitalisation boursière : US$10.0b

10x Genomics Gestion

Gestion contrôle des critères 4/4

Le PDG 10x Genomics est Serge Saxonov, nommé en Jul2012, a un mandat de 14.17 ans. La rémunération annuelle totale est $ 6.33M, composée du salaire de 10.7% et des bonus 89.3%, y compris les actions et options de la société. détient directement 3.18% des actions de la société, d'une valeur de $ 316.88M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.7 ans et 7.3 ans.

Informations clés

Serge Saxonov

Directeur général

US$6.3m

Rémunération totale

Pourcentage du salaire du PDG10.65%
Durée du mandat du directeur général14.2yrs
Propriété du PDG3.2%
Durée moyenne d'occupation des postes de direction2.7yrs
Durée moyenne du mandat des membres du conseil d'administration7.3yrs

Mises à jour récentes de la gestion

Recent updates

Mise à jour du récit • Sep 17

TXG: Rich Multiples Will Clash With Slower Single Cell Recovery Expectations

The analyst price target framework for 10x Genomics has shifted higher, with fair value moving from $17.00 to $40.00 as analysts factor in updated growth assumptions, higher projected profit margins, and richer sector P/E multiples supported by recent research that highlights Atera demand, consumable durability, and the broader life science tools backdrop. Analyst Commentary Recent research coverage on 10x Genomics shows a mix of optimism around new products and a more measured stance on the company’s more established lines of business.
Mise à jour du récit • Sep 03

TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook

The analyst price target for 10x Genomics has moved from $50 to about $68, with analysts pointing to updated models that reflect the Atera launch, spatial and consumables demand, and the company's positioning around AI driven drug development as key supports for the higher valuation assumptions. Analyst Commentary Recent Street research on 10x Genomics points to a cluster of price target increases tied to Atera, spatial biology adoption, and updated revenue models.
Mise à jour du récit • Aug 20

TXG: Elevated AI Demand Expectations Will Pressure Overextended Near Term Setup

Analysts have lifted the fair value estimate for 10x Genomics from $41.54 to $49.54, reflecting a series of higher price targets that reference stronger revenue assumptions, slightly improved profit margins, and interest in the company's role in AI driven drug development and Atera demand. Analyst Commentary Recent Street research on 10x Genomics points to a mix of optimism and caution.
Seeking Alpha • Aug 20

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Summary Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG’s valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution. Read the full article on Seeking Alpha
Article d’analyse • Aug 12

US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results

A week ago, 10x Genomics, Inc. ( NASDAQ:TXG ) came out with a strong set of quarterly numbers that could potentially...
Mise à jour du récit • Aug 06

TXG: Elevated 2027 Expectations And Product Transitions Will Pressure Near Term Setup

Analyst price targets for 10x Genomics have moved sharply higher, with the fair value estimate rising from about $20.14 to $41.54 as analysts factor in higher sector multiples, expectations around single cell demand, and potential contribution from the Atera platform in coming years. Analyst Commentary Recent research on 10x Genomics shows a cluster of higher price targets, but with mixed views on how much upside is left relative to execution risk and current valuation levels.
Mise à jour du récit • Jul 23

TXG: Cancer Collaboration And Tools Strength Will Support Balanced Outlook

The analyst price target for 10x Genomics has been raised from $45.00 to $50.00. Analysts generally point to higher sector multiples, expectations that single cell and the Atera platform could support future demand, and updated earnings models ahead of upcoming results as key reasons for the change.
Mise à jour du récit • Jul 09

TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook

Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.
Mise à jour du récit • Jun 25

TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook

Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.
Mise à jour du récit • Jun 11

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.
Mise à jour du récit • May 28

TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026

Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.
Article d’analyse • May 13

Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results

10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...
Mise à jour du récit • May 12

TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations

Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.
Mise à jour du récit • Apr 21

TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026

The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.
Mise à jour du récit • Apr 06

TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook

Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.
Mise à jour du récit • Mar 23

TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup

Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.
Mise à jour du récit • Mar 07

TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations

Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.
Mise à jour du récit • Feb 21

TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment

The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.
Mise à jour du récit • Feb 07

TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside

Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.
Article d’analyse • Jan 24

10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...
Mise à jour du récit • Jan 23

TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential

Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.
Mise à jour du récit • Jan 08

TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment

Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.
Mise à jour du récit • Dec 25

TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance

Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.
Mise à jour du récit • Dec 11

TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook

Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.
Mise à jour du récit • Nov 27

TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure

Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.
Article d’analyse • Nov 14

There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump

10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...
Mise à jour du récit • Nov 09

TXG: Institutional Interest And New Assay Expected To Influence Future Performance

Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.
Mise à jour du récit • Aug 08

Advanced Genomics Tools Will Shape Future Precision Medicine

Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.

Analyse de la rémunération des PDG

Comment la rémunération de Serge Saxonov a-t-elle évolué par rapport aux bénéfices de 10x Genomics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2026n/an/a

-US$75m

Mar 31 2026n/an/a

-US$23m

Dec 31 2025US$6mUS$674k

-US$44m

Sep 30 2025n/an/a

-US$76m

Jun 30 2025n/an/a

-US$85m

Mar 31 2025n/an/a

-US$157m

Dec 31 2024US$8mUS$625k

-US$183m

Sep 30 2024n/an/a

-US$183m

Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Rémunération vs marché: La rémunération totale de Serge ($USD 6.33M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 14.74M ).

Rémunération et revenus: La rémunération de Serge a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Serge Saxonov (49 yo)

14.2yrs
Titularisation
US$6,329,244
Compensation

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Serge Saxonov
Co-Founder14.2yrsUS$6.33m3.18%
$ 316.9m
Benjamin Hindson
Co-Founder14.2yrsUS$2.60m2.55%
$ 254.5m
Adam Taich
CFO, Treasurer2.1yrsUS$2.23m0.085%
$ 8.4m
Jim Goodrich
Chief of Global Operations2.7yrspas de donnéespas de données
Michael Schnall-Levin
Founding Scientist & CTO4.7yrspas de donnéespas de données
Cassie Corneau
Manager of Investor Relations & Strategic Financeno datapas de donnéespas de données
Randy Wu
General Counsel and Secretaryless than a yearpas de donnéespas de données
Mennah Moustafa
Chief Commercial Officer2.1yrspas de donnéespas de données
Jens Durruthy
Associate Director of Product Managementno datapas de donnéespas de données
2.7yrs
Durée moyenne de l'emploi
51yo
Âge moyen

Gestion expérimentée: L'équipe de direction de TXG est considérée comme expérimentée (ancienneté moyenne 2.7 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Serge Saxonov
Co-Founder14.2yrsUS$6.33m3.18%
$ 316.9m
Benjamin Hindson
Co-Founder14.2yrsUS$2.60m2.55%
$ 254.5m
Kimberly Popovits
Independent Director6.5yrsUS$216.32k0.022%
$ 2.2m
John Stuelpnagel
Independent Chairman13.1yrsUS$283.41k1.86%
$ 186.0m
Shehnaaz Suliman
Independent Director7.1yrsUS$210.99k0.018%
$ 1.8m
Alan Mateo
Independent Director2.3yrsUS$208.27k0.052%
$ 5.2m
Sridhar Kosaraju
Independent Director7.4yrsUS$223.32k0.046%
$ 4.6m
Sarah Polonius-Teichmann
Independent Director2.2yrsUS$198.32kpas de données
7.3yrs
Durée moyenne de l'emploi
52.5yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TXG sont considérés comme expérimentés (ancienneté moyenne 7.3 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/21 16:08
Cours de l'action en fin de journée2026/09/21 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

10x Genomics, Inc. est couverte par 26 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Luke SergottBarclays
Avantika DhabariaBofA Global Research
Michael RyskinBofA Global Research